Amneal Pharmaceuticals Partners with Knight Therapeutics for CREXONT Expansion in Canada and Latin America

Amneal Pharmaceuticals has partnered with Knight Therapeutics for the regulatory approval and commercialization of CREXONT, a new oral medication for Parkinson's disease, in Canada and Latin America. The Canadian market for CREXONT is estimated to be over $50 million, while the Brazilian market exceeds $120 million. The collaboration marks a significant step in expanding Amneal's footprint in the neurological treatment sector within these regions.

Knight Therapeutics Inc. (TSX: GUD) and Amneal Pharmaceuticals Inc. (Nasdaq: AMRX) have announced a strategic partnership to secure exclusive rights for the regulatory approval and commercialization of CREXONT, a novel oral medication for Parkinson's disease, in Canada and Latin America. The collaboration marks a significant step in expanding Amneal's footprint in the neurological treatment sector within these regions.

CREXONT is an innovative oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules designed to treat Parkinson's disease. The unique design of CREXONT allows for rapid onset while leveraging a mucoadhesive polymer for slow LD release, potentially enabling longer LD absorption in the gut. The Canadian market for CREXONT is estimated to be over $50 million, while the Brazilian market exceeds $120 million, according to IQVIA [1].

Knight Therapeutics, a pan-American specialty pharmaceutical company, has submitted its New Drug Submission (NDS) for CREXONT to Health Canada, which has been accepted for review. The company is also working to submit the marketing authorization application in Mexico and Brazil during 2025. The collaboration with Amneal Pharmaceuticals will allow Knight to focus on its core competencies while Amneal leverages its extensive distribution network to bring CREXONT to market.

"The submission of CREXONT in Canada highlights Knight's ongoing commitment to enhancing our central nervous system (CNS) portfolio," said Samira Sakhia, President and CEO of Knight. "With a significant unmet medical need in Parkinson’s disease treatment, CREXONT will offer a valuable new therapeutic option for the patients."

Amneal Pharmaceuticals, known for its expertise in generic and branded pharmaceuticals, will benefit from this partnership by expanding its presence in the neurological treatment sector. The company's Q1 revenues grew by 5% to $695 million, with adjusted EBITDA increasing by 12% to $170 million. The launch of CREXONT has exceeded expectations, with market share growth in the Parkinson's disease treatment segment [2].

Wall Street analysts forecast an average target price of $10.80 for Amneal Pharmaceuticals, with an average brokerage recommendation of "Outperform." The estimated GF Value for Amneal Pharmaceuticals in one year is $2.80, suggesting a downside of 66.02% from the current price of $8.24 [2].

The partnership between Knight Therapeutics and Amneal Pharmaceuticals is expected to bring a significant improvement in the treatment options available for Parkinson's disease patients in Canada and Latin America. The innovative design of CREXONT offers a promising alternative to existing treatments, potentially improving patient outcomes and reducing the burden of this progressive neurological disorder.

References:
[1] https://www.globenewswire.com/news-release/2025/07/18/3117816/0/en/Knight-Therapeutics-Announces-Filing-of-New-Drug-Submission-for-CREXONT-Carbidopa-and-Levodopa-Extended-Release-Capsules-in-Canada.html
[2] https://www.gurufocus.com/news/2987149/amneal-pharmaceuticals-amrx-partners-with-knight-for-crexont-expansion-amrx-stock-news